Aerovate Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Aerovate Therapeutics, Inc. carries a market capitalization of 77.68M, placing it among publicly traded companies globally. Its enterprise value stands at 2.56B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 77.68M |
| Enterprise Value | 2.56B |
Share Statistics
Aerovate Therapeutics, Inc. currently has 28.99M shares outstanding.
| Shares Outstanding | 28.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -11.33 |
| P/TBV Ratio | 34.55 |
| P/FCF Ratio | -37.09 |
| P/OCF Ratio | -37.09 |
Financial Position
Aerovate Therapeutics, Inc. maintains a current ratio of 20.93, meaning it holds 20.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 20.93 |
| Quick Ratio | 20.54 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -67.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Aerovate Therapeutics, Inc.'s stock has declined approximately -99.52351% over the past 52 weeks. The 50-day moving average sits at 88.74, while the 200-day moving average is 82.18.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.52351% |
| 50-Day Moving Average | 88.74 |
| 200-Day Moving Average | 82.18 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -74.31M, while operating income came in at -74.60M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -74.60M |
| Pretax Income | -69.57M |
| Net Income | -69.63M |
| EBITDA | -74.31M |
| EBIT | -74.60M |
| Earnings Per Share (EPS) | -2.45 |
Balance Sheet
Aerovate Therapeutics, Inc. holds 78.62M in cash and equivalents against 417,000.00 in total debt, resulting in a net debt position of -33.75M. Total book value stands at -233.05M, with working capital of 76.29M providing operational flexibility.
| Cash & Cash Equivalents | 78.62M |
| Total Debt | 417,000.00 |
| Net Debt | -33.75M |
| Equity (Book Value) | -233.05M |
| Book Value Per Share | -8.19 |
| Working Capital | 76.29M |
Cash Flow
Aerovate Therapeutics, Inc. produced -71.20M in operating cash flow over the past twelve months.
| Operating Cash Flow | -71.20M |
| Capital Expenditures | N/A |
| Free Cash Flow | -71.20M |
| FCF Per Share | -2.50 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.96 |
| FCF Yield | -2.70 |
Stock Splits
Aerovate Therapeutics, Inc.'s most recent stock split took place on April 29, 2025 with a 35:1 split ratio.
| Last Split Date | 4/29/2025 |
| Split Ratio | 35:1 |
Scores
Aerovate Therapeutics, Inc. posts an Altman Z-Score of 400.49, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 400.49 |